ArticleClinical rheumatology2013
Cost-minimisation analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who have had an insufficient response or intolerance to oral methotrexate.
Ray Fitzpatrick et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
16 papers cite it
this papercites it